CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Camostat MesylateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1005 Graded exercise test Wiki 1.00
drug590 Cloth Face Mask Wiki 1.00
drug1539 N-95 Respirator Wiki 1.00
drug1488 Microcrystalline Cellulose, NF Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.30
D001778 Blood Coagulation Disorders NIH 0.30

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.30

There is one clinical trial.

Clinical Trials

1 The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.

NCT04435015 Coagulopathy Cardiovascular Complication COVID-19 Drug: Camostat Mesylate Drug: Microcrystalline Cellulose, NF
MeSH:Hemostatic Disorders Blood Coagulation Disorders
HPO:Abnormality of coagulation Abnormality of the coagulation cascade

Primary Outcomes

Description: The sum percent change in D-Dimer over 7 days will be compared to day 1

Measure: Percent change in plasma D-Dimer

Time: 7 days

Secondary Outcomes

Description: The first assessment on mortality and complications will be carried out 3 months after the start of the study.

Measure: Overall Safety and adverse event

Time: 3 months

Description: Percent change in fibrinogen over 7 days compared to day 1

Measure: Change in plasma Fibrinogen levels

Time: 7 days

Description: Percent change in troponin over 7 days compared to day 1

Measure: Change in plasma troponin

Time: 7 days

Description: New onset cardiomyopathy defined by a reduction of EF by greater than 10% or less than 45% will be measured

Measure: New onset cardiomyopathy

Time: 7 days

Description: Days with hypoxia (Room Air O2 Sat<93%) or days intubated

Measure: Duration of intubation

Time: 7 days

Description: The number of days in the intensive care unit

Measure: Length of stay in the intensive care unit

Time: 28 days

Description: The number of days since admission to discharge

Measure: Time to discharge from hospital

Time: 30 days

Description: The ocurrence of major adverse cardiovascular events (MACE): MI, stroke, CHF, PCI, death from cardiovascular disease will be studied.

Measure: Occurrence of major adverse cardiovascular events

Time: 7 days

Related HPO nodes (Using clinical trials)

HP:0001928: Abnormality of coagulation
Genes 218
STIM1 SPTB PGM1 F7 EPB42 NOP10 MPI SERPINC1 NGLY1 STAT5B PEX16 RBM8A PTH1R A2ML1 RRAS2 OSTM1 DPM2 ANO6 GPR35 WRAP53 PML GP1BA F2 COG8 GNA14 F10 RFT1 HADH TERT PEX1 ALG2 PEX5 PROC ORAI1 F7 ALDOB PLG VKORC1 SRD5A3 PEX6 PEX26 AKR1D1 TCF4 F5 PROS1 GP9 BCOR RFT1 ITGA2B THBD ALG12 CFI IRF2BP2 PEX19 HRG F8 LMAN1 HSD3B7 MYD88 LMAN1 ZBTB16 MRAS PEX10 F2 HMGCL HAVCR2 STX11 AGA F9 SERAC1 AGGF1 LARS1 KLKB1 NUMA1 ABCC2 RARA F11 NRAS MST1 PEX12 SSR4 NBAS F13A1 ATP6V0A2 RTEL1 CYP7B1 F11 TEK CBL FIP1L1 NR1H4 SSR4 F8 UNC13D SRD5A3 TINF2 F13A1 HSD3B7 NPM1 SLC25A13 ANK1 CYP7B1 PMM2 ITGB3 EFL1 SOS2 PIGA VPS33A PEX14 PRF1 ATP6V1A GPC1 GNE PEX11B FAH GGCX HBB B4GALT1 MCFD2 PRKAR1A IDH1 MAP2K1 RTEL1 RASA2 XIAP LMNA NABP1 FLNA SLC30A10 VWF NPM1 SLC25A15 GFI1B UQCRFS1 NBEAL2 F8 DKC1 STAT3 PLAT CFH TFAM ATP6V0A2 GP1BA CACNA1S FGG KRAS GGCX DOLK TBL1XR1 FGA BRAF VWF F12 GATA2 ACD SOS1 TERC MPDU1 RYR1 PROS1 DPM1 PTPN11 LZTR1 PTPN11 TERT GGCX HMGCL DDOST F10 F9 MGAT2 AHCY FGB PARN IDH2 GATA6 BCS1L SLC4A1 RYR1 RAF1 GP1BB SPTA1 DLD F8 SERPINF2 PEX13 HELLPAR ALG6 COG4 GP1BB ATP6V1E1 RIT1 GP9 SERPINC1 ACAD9 NHP2 SLC7A7 PEX3 DPAGT1 PARN PROC TRMU CD46 RRAS F13B LYST USB1 ZMPSTE24 CTC1 PEX2 PMM2 AMACR DKC1 MCFD2 F13B F5 TINF2 HAVCR2
Protein Mutations 0
SNP 0
HP:0003256: Abnormality of the coagulation cascade
Genes 139
PRF1 ATP6V1A GPC1 GNE SPTB PGM1 F7 GGCX EPB42 MPI SERPINC1 NGLY1 STAT5B MCFD2 PRKAR1A MAP2K1 OSTM1 XIAP DPM2 ANO6 LMNA NABP1 FLNA SLC30A10 VWF GPR35 PML GP1BA SLC25A15 GFI1B F2 COG8 GNA14 F10 NBEAL2 RFT1 F8 HADH STAT3 CFH TFAM ATP6V0A2 PROC F7 GP1BA ALDOB CACNA1S PLG FGG VKORC1 SRD5A3 TBL1XR1 FGA AKR1D1 BRAF VWF TCF4 F5 PROS1 GP9 BCOR F12 ITGA2B MPDU1 RYR1 CFI IRF2BP2 PROS1 DPM1 F8 PTPN11 LMAN1 HSD3B7 LMAN1 HMGCL ZBTB16 DDOST F10 F9 MGAT2 F2 AHCY HMGCL FGB BCS1L HAVCR2 SLC4A1 RYR1 GP1BB STX11 SPTA1 AGA F9 F8 SERAC1 HELLPAR LARS1 NUMA1 RARA F11 MST1 SSR4 ALG6 COG4 GP1BB ATP6V1E1 NBAS F13A1 GP9 SERPINC1 ATP6V0A2 ACAD9 SLC7A7 CYP7B1 F11 DPAGT1 PROC TRMU FIP1L1 NR1H4 CD46 F13B F8 ZMPSTE24 UNC13D SRD5A3 F13A1 NPM1 SLC25A13 ANK1 PMM2 PMM2 AMACR ITGB3 EFL1 MCFD2 F13B F5 HAVCR2
Protein Mutations 0
SNP 0